



Vaccitech to Present at Upcoming October Investor & Scientific Conferences

October 3, 2022

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.

Event: Maryland Life Sciences Bio Innovation Conference, Bethesda
Date: Monday, October 3 – Tuesday, October 4
Panel: Emerging Vaccine Opportunities in Modulating the Immune System
Participant: Dr. Geoffrey Lynn
Time: 3:30 – 4:15 p.m. EDT on Monday, October 3

Event: World Vaccine Congress, Barcelona, Spain
Date: Tuesday, October 11 – Friday, October 14
Presentation: A Novel Approach for Focusing Antibody Responses as a Pan-Coronavirus Vaccine
Participant: Dr. Hugh Welles
Time: 10:45 a.m. EDT on Wednesday, October 12

Presentation: Novel Cancer Vaccine Program: Updates HPV Cancer Vaccine
Participant: Dr. Geoffrey Lynn
Time: 7:00 a.m. EDT on Friday, October 14

Event: HC Wainwright 3rd Annual Hepatitis B Virus Conference, Virtual
Date: Tuesday, October 18
Presentation: Fireside Chat
Participant: Dr. Thomas G. Evans
Time: 09:30 a.m. EDT on Tuesday, October 18

Event: BIO-Europe, Leipzig, Germany
Date: Monday, October 24 – Wednesday, October 26
Attending: Nick Fullenkamp
Available to participate in 1x1 partnering meetings

About Vaccitech plc

Vaccitech ("the Company") is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important role. The company's proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:

Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Katie Larch / Robert Flamm, Ph.D., Burns McClellan, Inc. (U.S.)
Email: klarch@burnsmc.com / rflamm@burnsmc.com

Gemma Brown, CFO, Vaccitech
Email: IR@vaccitech.co.uk

